Please use this identifier to cite or link to this item:
|Title:||Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma||Authors:||Back, Michael F ;Perry, J.R.;Laperriere, N.;O'Callaghan, C.J.;Brandes, A.A.;Menten, J.;Phillips, C.;Fay, M.;Nishikawa, R.;Cairncross, J.G.;Roa, W.;Osoba, D.;Rossiter, J.P.;Sahgal, A.;Hirte, H.;Laigle-Donadey, F.;Franceschi, E.;Chinot, O.;Golfinopoulos, V.;Fariselli, L.;Wick, A.;Feuvret, L.;Tills, M.;Winch, C.;Baumert, B.G.;Wick, W.;Ding, K.;Mason, W.P.||Affliation:||Central Coast Local Health District
|Issue Date:||Mar-2017||Source:||376(11):1027-1037||Journal title:||New England Journal of Medicine||Department:||Central Coast Cancer Centre||Abstract:||BACKGROUND: Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter courses of radiotherapy are commonly used, but the benefit of adding temozolomide to a shorter course of radiotherapy is unknown. METHODS: We conducted a trial involving patients 65 years of age or older with newly diagnosed glioblastoma. Patients were randomly assigned to receive either radiotherapy alone (40 Gy in 15 fractions) or radiotherapy with concomitant and adjuvant temozolomide. RESULTS: A total of 562 patients underwent randomization, 281 to each group. The median age was 73 years (range, 65 to 90). The median overall survival was longer with radiotherapy plus temozolomide than with radiotherapy alone (9.3 months vs. 7.6 months; hazard ratio for death, 0.67; 95% confidence interval [CI], 0.56 to 0.80; P<0.001), as was the median progression-free survival (5.3 months vs. 3.9 months; hazard ratio for disease progression or death, 0.50; 95% CI, 0.41 to 0.60; P<0.001). Among 165 patients with methylated O(6)-methylguanine-DNA methyltransferase (MGMT) status, the median overall survival was 13.5 months with radiotherapy plus temozolomide and 7.7 months with radiotherapy alone (hazard ratio for death, 0.53; 95% CI, 0.38 to 0.73; P<0.001). Among 189 patients with unmethylated MGMT status, the median overall survival was 10.0 months with radiotherapy plus temozolomide and 7.9 months with radiotherapy alone (hazard ratio for death, 0.75; 95% CI, 0.56 to 1.01; P=0.055; P=0.08 for interaction). Quality of life was similar in the two trial groups. CONCLUSIONS: In elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone. (Funded by the Canadian Cancer Society Research Institute and others; ClinicalTrials.gov number, NCT00482677 .).||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1255||DOI:||10.1056/NEJMoa1611977||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/28296618||ISSN:||0028-4793||Publicaton type:||Journal Article||Keywords:||Cancer
|Study or Trial:||Clinical Trial|
|Appears in Collections:||Oncology / Cancer|
Show full item record
checked on Jan 28, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.